News summary

Novo takes 26 obesity studies to ObesityWeek

Source: Longevity Technology • Published: 10 Nov 2026, 17:14

Summarized by Masters of Longevity from Longevity Technology.

Novo reported 26 obesity-study findings including real-world and pediatric data.

Novo takes 26 obesity studies to ObesityWeek
Key Takeaways
  • Novo presented 26 obesity studies including real-world pill data.
  • An investigational weight-loss drug was studied at lower doses.
  • Some trial data included children as young as six years old.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.